Canaccord Genuity Initiates Coverage On BridgeBio Pharma with Buy Rating, Announces Price Target of $104
Benzinga Newsdesk 5 months ago
NewsPrice TargetInitiationAnalyst Ratings
Canaccord Genuity analyst Whitney Ijem initiates coverage on BridgeBio Pharma (NASDAQ:BBIO) with a Buy rating and announces Price Target of $104.
Canaccord Genuity analyst Whitney Ijem initiates coverage on BridgeBio Pharma (NASDAQ:BBIO) with a Buy rating and announces Price Target of $104.